Isis therapy for spinal muscular atrophy provides encouraging results

Isis Pharmaceuticals' (ISIS) ISIS-SMN treatment appears to have increased muscle function in an ongoing multiple-dose Phase 1b/2a study of children with spinal muscular atrophy, interim results demonstrate.

In addition, results from a biomarker assay show an increase of SMN protein (Survival of Motor Neuron) in the cerebral spinal fluid. The protein is particularly important for the maintenance of motor-neuron nerve cells, which control muscle movement.

The results give Isis "further confidence to advance ISIS-SMNRx into a Phase 3 program" says CFO Lynne Parshall. That trial is due to start later this year. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs